Patients with hepatocellular carcinoma, cirrhosis, portal hypertension
Conditions
Interventions
None listed
Sponsors
Chiba university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with hepatocellular carcinoma or with conditions of cirrhosis or portal hypertension 2) Patients who have undergone TACE between July 1, 2022 and December 31, 2024, and for whom moving images are stored 3) Patients who have undergone hepatic venography between July 1, 2022 and December 31, 2024, and for whom moving images are stored.
Exclusion criteria
Exclusion criteria: 1) With unclear images 2) Those with missing values
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of artifact reduction compared to conventional DSA images (5-point scale) The evaluation will be carried out by two doctors with either gastroenterology, hepatology, or radiology expertise. The reduction effect will be evaluated on a three-point scale based on whether the contrast effect of the following structures can be visually confirmed for both the conventional method and the test method, and the total score will be calculated. (1)Angiography during TACE treatment Tumor contrast effect 0,Insufficient (unknown structure) 1,Standard (unclear structure) 2,Sufficient (clear structure) Hepatic artery contrast effect 0: Up to 1st branch 1: Up to 2nd branch 2: Up to 3rd branch Diaphragm artifact 0,Present 1,Partially present 2,Absent Intestinal gas artifact 0,Present 1,Partially present 2,Absent (2)Angiography during hepatic venography Hepatic vein contrast effect 0,Up to 1st branch 1,Up to 2nd branch 2,Up to 3rd branch Diaphragm artifact 0,Present 1,Partially present 2,Absent Intestinal gas artifact 0,Present 1,Partially present 2,Absent | — |
Countries
Japan
Contacts
Public ContactHidem Unozawa
Chiba University Hospital Gastroenterology
Outcome results
None listed